Sign up
Quantellect · Congress · Trade Detail
NASDAQ: EDITEditas Medicine Inc
DemocratHouse

Daniel S. Goldman sold Editas Medicine Inc (NASDAQ: EDIT)

Daniel S. Goldman (D-NY), a U.S. Representative, has disclosed 1 trade in Editas Medicine Inc (EDIT) since 2023, a single sale, worth an estimated $8K in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts).

The trade highlighted here is a sale: Daniel S. Goldman sold $1,001 - $15,000 of Editas Medicine Inc (NASDAQ: EDIT) on April 10, 2023. Since that trade, EDIT is down -60.78% against the S&P 500 up +85.07%, an outperformance of -145.85%.

Tracked by Quantellect from public STOCK Act disclosures.

Data updated

EDIT trades
1
Disclosed Vol
$8K
Buys
0
0%
Sells
1
100%
Buy / Sell
0.00
ratio
First → Last
2023

Daniel S. Goldman's EDIT trades vs the price

EDIT is down -60.78% since Daniel S. Goldman sold on April 10, 2023, versus +85.07% for the S&P 500.

Performance since this trade

Price change since trade
-60.78%
S&P 500 change since trade
+85.07%
Outperformance vs S&P 500
-145.85%

All Daniel S. Goldman EDIT trades

TradedTypeSizeReturnEst. profit
April 10, 2023SELL$6.63-60.78%—

Estimated profit is shown for buys only, marked to the latest close. It is an estimate and does not net later sells, taxes, or fees.

Free BullishWhales account
Track Congress across your whole watchlist, not just one stock.
Get a filing alert the moment a member of Congress discloses a trade, plus the full 5-year history and Tide scores on 4,500+ tickers.
Sign up free

Daniel S. Goldman & EDIT trading FAQ

Is it legal for Daniel S. Goldman to trade Editas Medicine Inc (EDIT) stock?

Yes. Members of Congress are allowed to trade individual stocks, including Editas Medicine Inc (EDIT), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. Quantellect tracks those disclosures; this page does not imply the trade was improper.

When did Daniel S. Goldman sell EDIT?

Daniel S. Goldman disclosed a sale of $1,001 - $15,000 of Editas Medicine Inc (EDIT) on April 10, 2023, according to public STOCK Act filings.

How has EDIT performed since Daniel S. Goldman's trade?

Since Daniel S. Goldman sold EDIT on April 10, 2023, the stock is down -60.78%, versus +85.07% for the S&P 500 over the same period, an outperformance of -145.85%.

How soon must members of Congress disclose a trade?

Under the STOCK Act, members of Congress must publicly report a covered transaction within 45 days of the trade. Filings can still be delayed, amended, or contain errors.

Where can I see all congressional EDIT trades?

Quantellect tracks every disclosed congressional trade in Editas Medicine Inc (EDIT) on the Editas Medicine Inc congressional trading page, which aggregates filings across all members of Congress.

Daniel S. Goldman's EDIT tradesAll congressional filings for Editas Medicine IncDaniel S. Goldman's full profile

Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. Estimated prices and post-trade returns are derived algorithmically from public filings and end-of-day market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.